Capricor Therapeutics Inc., of Los Angeles, disclosed positive six-month safety and adverse event data from its ongoing DYNAMIC (Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells) trial evaluating CAP-1002 in patients with advanced heart failure.